Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates

Learn how ophthalmologists and optometrists can work with hematologist/oncologists to recognize and optimally manage ocular toxicities in patients receiving antibody&ndash drug conjugates for the treatment of cancer with expert slides and on-demand Webcast capturing a live CCO Webinar plus a focused expert-authored commentary.

Share

Program Content

Activities

Eye Toxicity With ADCs
Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: January 20, 2021

Expires: January 19, 2022

Activities

<i>EP</i>: ADC Ocular Toxicity
ExpressPoints: Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

ADC Ocular Toxicity
Antibody–Drug Conjugates in the Treatment of Cancer and Mechanisms of Ocular Toxicity
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Managing ADC Eye Toxicity
Monitoring and Management of Ocular Toxicity from Antibody-Drug Conjugates
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Activities

FAQs: ADC Ocular Toxicity
Answering Your Questions: Ocular Toxicity With Antibody–Drug Conjugates
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 25, 2021

Expires: January 24, 2022

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline